

SPIRIT – Assessing clinical parameters associated with using IDegLira in patients with Type 2 Diabetes in a real-world setting in Colombia

Alex Ramírez-Rincón¹, Diana Henao-Carrillo², Miguel Omeara³, Julio Oliveros⁴, José Assaf⁴, Jaime E. Ordóñez⁵, Preethy Prasad⁶, María Alejandra Alzate⁷

¹ Universidad Pontificia Bolivariana, Medellín, Colombia

² Pontificia Universidad Javeriana, Bogotá D.C., Colombia

³ Universidad del Rosario, Bogotá D.C., Colombia

⁴ Universidad Autónoma de Bucaramanga, Bucaramanga, Colombia

⁵ True Consulting, Medellín, Colombia

⁶ Novo Nordisk Global Business Services, Bangalore, India

⁷ Novo Nordisk LATAM Regional Office, Bogotá, Colombia

Corresponding author: María Alejandra Alzate. ma.alzate20@gmail.com . Calle 125 #19-24, Bogotá, Colombia

ORCID:

Alex Ramírez-Rincón 0000-0002-3925-6201

Diana Henao Carrillo 0000-0002-1353-148X

Miguel Omeara 0000-0002-8345-6155

Julio Oliveros

José Assaf

Jaime E. Ordóñez 0000-0002-4425-2555

Preethy Prasad

María Alejandra Alzate 0009-0006-6247-6049

Supplementary file

Centers contribution and IRB approval

Medical Unit	n	%	IRB approval date
101 - Instituto Cardiología La Cardio	17	9.7	24 March 2022
102 - FRC Unidad ambulatoria	4	2.3	03 March 2022
103 - Centro de Investigaciones BLUECARE S.A.S.	4	2.3	04 February 2022
104 - Hospital Universitario San Ignacio	19	10.9	04 April 2022
105 - IPS Cabecera	50	28.6	03 March 2022
106 - FUNCENTRA	9	5.1	09 February 2022
107 - Clínica Integral de Diabetes	10	5.7	03 March 2022
109 - Salud Total EPS	36	20.6	03 March 2022
113 - Centro De Diabetes y Metabolismo CEDYM SAS	11	6.3	26 May 2022
114 - Ayudas Diagnosticas SURA	15	8.6	27 May 2022